Next Article in Journal
Anthraquinone Derivatives from a Marine-Derived Fungus Sporendonema casei HDN16-802
Next Article in Special Issue
A Study for the Access to a Semi-synthetic Regioisomer of Natural Fucosylated Chondroitin Sulfate with Fucosyl Branches on N-acetyl-Galactosamine Units
Previous Article in Journal
Butenolide Derivatives with α-Glucosidase Inhibitions from the Deep-Sea-Derived Fungus Aspergillus terreus YPGA10
Previous Article in Special Issue
New 1,2,4-Oxadiazole Nortopsentin Derivatives with Cytotoxic Activity
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Marine Drugs
Volume 17
Issue 6
10.3390/md17060333
marinedrugs-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis and Preliminary Biological Evaluation of Two Fluoroolefin Analogs of Largazole Inspired by the Structural Similarity of the Side Chain Unit in Psammaplin A

by
Bingbing Zhang
1,†,
Guangsheng Shan
1,†,
Yinying Zheng
1,†,
Xiaolin Yu
1,2,
Zhu-Wei Ruan
1,
Yang Li
1 and
Xinsheng Lei
1,3,*
1
School of Pharmacy, Fudan University, 826 Zhangheng Road, Pudong Zone, Shanghai 201203, China
2
College of Chemistry and Molecular Engineering, Zhengzhou University, Zhengzhou 450001, China
3
Key Laboratory of Synthetic Chemistry of Natural Substances, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to the work.
Mar. Drugs 2019, 17(6), 333; https://doi.org/10.3390/md17060333
Submission received: 15 May 2019 / Revised: 27 May 2019 / Accepted: 28 May 2019 / Published: 3 June 2019
(This article belongs to the Special Issue Synthesis of Marine Natural Products and Analogues)
Browse Figures
Review Reports Versions Notes

Abstract

:
Largazole, isolated from a marine Cyanobacterium of the genus Symploca, is a potent and selective Class I HDAC (histone deacetylation enzymes) inhibitor. This natural 16-membered macrocyclic depsipeptide features an interesting side chain unit, namely 3-hydroxy-7-mercaptohept-4-enoic acid, which occurs in many other natural sulfur-containing HDAC inhibitors. Notably, one similar fragment, where the amide moiety replaces the trans alkene moiety, appears in Psammaplin A, another marine natural product with potent HDAC inhibitory activities. Inspired by such a structural similarity, we hypothesized the fluoroolefin moiety would mimic both the alkene moiety in Largazole and the amide moiety in Psammaplin A, and thus designed and synthesized two novel fluoro olefin analogs of Largazole. The preliminary biological assays showed that the fluoro analogs possessed comparable Class I HDAC inhibitory effects, indicating that this kind of modification on the side chain of Largazole was tolerable.

Graphical Abstract

1. Introduction

The regulation of histone-tailed lysine acetylation by histone acetyltransferases (HATs) and histone deacetylases (HDACs) plays a key role in the biochemistry of life process [1]. So far, at least 18 HDAC isoforms have been discovered, including Zn2+-dependent Class I (HDAC1, 2, 3, 8), Class II (class IIa: HDAC4, 5, 7, 9; class IIb: HDAC6, 10) and Class IV (HDAC11) [2]. Although the function of individual HDAC isoforms is not fully understood in cell and cancer biology, several pan-selective HDAC inhibitors, such as SAHA (Vorinostat), Belinostat, Panobinostat, Chidamide and Romidepsin (FK228), have been approved for the treatment of cutaneous T-cell lymphoma [2,3,4]. In principle, the class- and even isoform-specific HDAC inhibitors are hypothesized to be more beneficial in cancer therapy [5,6,7].
In 2008, Leusch’s group first discovered Largazole from a marine Cyanobacterium of the genus Symploca [8,9]. Largazole shows potent and highly selective inhibitory activities against Class I HDACs and displays superior anticancer properties, attracting great attention among many organic and medicinal chemists [10,11,12,13,14]. Largazole possesses a number of unusual structural features, including a 3-hydroxy-7-mercaptohept-4-enoic acid unit and a 16-membered macrocyclic depsipeptide moiety. Interestingly, this side chain unit also appears in several other natural HDAC inhibitors, including Romidepsin (FK228) [15], FR901375 [16,17], and Spiruchostatins (Figure 1) [18]. Psammaplin A, a member of a family of natural products isolated from some marine sponges, contains a similar side chain but with an amide bond instead of an olefin moiety (Figure 1) [19]. All these natural HDAC inhibitors can release a free sulfhydryl residue in vitro and in vivo through either reductive cleavage of the disulfide or hydrolysis of thioester, which is believed to exert inhibitory effects by coordinating with zinc cation of the HDACs (Figure 1) [9,10,11,12,13,14,19].
Up to now, great effort has been made to modify the 16-membered macrocyclic depsipeptide moiety of Largazole to search for more selective HDAC inhibitors [20], but modification on the common side chain unit usually leads to the loss of activities through changing the chain length and the stereo-configuration of the double bond and the secondary alcohol, as well as the Zn2+-binding group [21,22,23,24,25,26], possibly due to limitation of the narrow hydrophobic tunnel of HDACs [27]. Inspired by the structural similarity of the side chain unit of Largazole and Psammaplin, we believed that the unit may play a common role in the inhibition of HDACs. However, our previous work also demonstrated a complete loss of activity when the alkene moiety in Largazole was replaced with the amide moiety [28]. Comparing with trans olefin, trans fluoroolefin is usually viewed as a superior bioisostere of amide bond based on the steric demand, bond length and angle [29], and furthermore, the replacement of the olefin with fluoroolefin has little influence on the rigid conformation of Largazole. Herein, we report our work on synthesis and preliminary biological evaluation of two novel fluoro olefin analogs of Largazole.

2. Results and Discussion

2.1. Chemistry

The synthesis of two fluoroolefin analogs of Largazole was accomplished according to Scheme 1. The key 4-fluoro analog of chiral 3-hydroxy/amino-7-mercaptohept-4-enoic acid was prepared from acrolein in four steps. Conjugate addition of triphenylmethanethiol (1) to acrolein 2 gave 3, which was directly used in the following Wittig-Type reaction [30] to give rise to 4 in 97% yield with Z- and E-isomer ratio of 3/1. Although the isomers could be carefully separated by column chromatography, most of the undesired E-isomer was found to be isomerized to the Z-isomer during the reduction with DIBALH in anhydrous THF. As a result, a mixture of Z- and E-isomer 4 was subjected to the reduction condition, giving the fluoro unsaturated aldehyde 5 in 86% yield. The asymmetric aldol condensation of 5 with acetyl Nagao’s auxiliary afforded 4-fluoro derivatives of chiral 3-hydroxy-7-mercaptohept-4-enoic acid (8 and 9) under Xie’s conditions [31,32] at a low temperature (−90 °C). The two diastereomers with 2:1 ratio as determined by 19F-NMR, were readily separated by silica gel column chromatography. The major chiral alcohol 8 was assigned to the desired S-configuration, while the minor alcohol 9 was designated as the R-configuration, according to the known reaction mechanism [32].
Compound 8 could be directly used for the next aminolysis as Nagao [31] and Xie [32] reported. Aminolysis of 8 with the thiazole-thiazoline fragment (10) [28] under the basic condition provided 11 in a good yield (70%). Then, esterification of the secondary alcohol in 11 with Fmoc-l-Valine (12a) or Fmoc-l-Phenylalanine (12a) pre-activated by 2,4,6-Cl3-C6H2COCl in the presence of DMAP and DIEPA [28], afforded 13a and 13b (yields: 65% and 60%, respectively). The structures of 13a and 13b were subsequently confirmed by 1H, 13C, COSY, HMQC and HMBC NMR spectra. Careful methyl ester hydrolysis of 13a or 13b in LiOH solution (THF/H2O) and removal of Fmoc group with Et2NH in CH2Cl2 resulted in the linear depsipeptide exposed at the N- and C-terminus, and after examination of several conditions, the system of HATU/HOAT/DIPEA in anhydrous CH2Cl2 solution (the concentration of cyclization precursor at about 0.001 M) was used for the macrolactamization, giving 14a and 14b (yields in three steps: 31% and 22%, respectively). Finally, deprotection of Trt group in 14a and 14b, using (i-Pr)3SiH (TIPS) and CF3CO2H in anhydrous CH2Cl2 solution, proceeded smoothly to afford the free thiol 15a and 15b (yields: 67% and 59%, respectively). The subsequent acylation with n-C7H15COCl under the standard condition led to the final fluoro analogs 16a and 16b (yields: 61% and 66%, respectively).

2.2. Biology

In vitro enzymatic assays on Largazole, Largazole free thiol and the related compounds (16a, 15a and 15b) were performed according to the known method [33] with SAHA (Vorinostat) as a reference. The inhibitory potencies against human HDACs (Class I HDACs: 1, 2, 3 and 8; one representative of Class II HDACs: HDAC 6) were evaluated, and the results are shown in Table 1 and Figure 2.
As expected, Largazole displayed relatively weaker HDACs inhibitory activities (IC50: from 120 to ca. 5000 nM) in vitro enzymatic assays. In contrast, Largazole thiol, the possibly activated species, displayed potent inhibitory activities on Class I HDACs with IC50 values in the nanomolar range (IC50 values of HDAC 1, 2, 3 and 8: 2.0, 9.5, 14.5 and 3.8 nM, respectively), and exhibited up to 61-fold selectivity over Class II HDACs exemplified by the IC50 value ratio of HDAC 1 versus HDAC 6. Most of these results were comparable with those reported [8,9,10,11,20,23,34] except HDAC 8 activity (3.8 nM verus 102 nM reported by Leusch). Despite that, the above results confirmed that Largazole thiol was a potent and selective Class I HDAC inhibitor, compared to SAHA.
Similar to Largazole, the fluoro ester 16a, also displayed relatively weaker HDACs inhibitory activities, and the fluoro thiol 15a exhibited highly potent inhibitory activities on Class I HDACs (IC50 values of HDAC 1, 2, 3 and 8: 4.4, 21.0, 39.2 and 8.3 nM, respectively) and almost the same selectivity over Class II HDACs (about 68-fold selectivity towards HDAC 1 over HDAC 6). These results indicated that the trans alkene moiety in Largazole could be replaced with trans fluoroolefin, which was significantly different from the previous results, because the replacement of trans olefin with an amide bond or aryl ring could lead to a complete loss of activities [14,28]. Furthermore, in contrast to those modifications on the chain length, the stereo-configuration of the double bond or the secondary alcohol of the linker [21,22,23,24,25,26], our modification was tolerable.
Compared with 15a, the other fluoro thiol (15b), with a benzyl group instead of an i-propyl group at C2-position of the macrocycle, also exhibited highly potent and selective inhibitory activities on Class I HDACs (IC50 values of HDAC 1, 2, 3, 8 and 6: 4.2, 16.2, 37.1, 8.3 and 338 nM, respectively). These results indicated that the modification at C2-position could be permitted to some extent with no loss of the activity and selectivity, which was also consistent with the results through the same modification on Laragzole thiol [25].
In the in vitro cell assays, considering the poor cell permeability, Largazole and its analog (16a), instead of their corresponding free thiols, were tested against several cell lines, and the results are shown in Table 2 and Figure 3. Largazole exhibited evident growth inhibition on A549, HCT116, MDA-MB-231, and SK-OV-3 cells with IC50 values of 0.46, 0.184, 1.37 and 0.034 µM, respectively. Comparing our data of HCT116 with Luesch’s [9], we found our data was about four-fold less potent than the reported data (0.184 µM versus 0.044 µM), indicating our assays were robust. However, in contrast to nanomolar-range potencies in the enzymatic assays, sub-micromolar-range potencies were observed in the cellular assay. We reasoned that Largazole might extracellularly release the free thiol to some extent in the cellular assays and then result in the diminished potencies due to the poor cell permeability of the free thiol.
As expected, the fluoro olefin analog (16a) gave comparable activities in the A549, HCT116, MDA-MB-231 cellular assay (IC50, A549: 0.52 µM, HCT116: 0.81 µM; MDA-MB-231: 3.85 µM) except SK-OV-3 (IC50, 0.25 µM). We reasoned that there may be more extracellular release of its free thiol in the case of SK-OV-3. Taken together, based on both enzymatic and cellular assays, we demonstrated that fluorine could be introduced into the alkene moiety of the Largazole with little sacrifice of the activities and selectivity. The kind of modification might be feasible for this family of the natural products (Figure 1) sharing the common side chain, and further study is under way.

3. Materials and Methods

3.1. Chemistry

The chemicals and reagents were purchased from Acros, Alfa Aesar, and National Chemical Reagent Group Co. Ltd., Shanghai, China, and used without further purification. Anhydrous solvents (THF, MeOH, DMF, CH2Cl2, and CH3CN) used in the reactions were dried and freshly distilled before use. All the reactions were carried out under Ar atmosphere, otherwise stated else. The progress of the reactions was monitored by TLC (silica-coated glass plates) and visualized under UV light, and by using iodine or phosphomolybdic acid. Melting points were measured on an SGW X-4 microscopy melting point apparatus without correction. 1H-NMR and 13C-NMR spectra were recorded either on a 400 MHz Varian Instrument at 25 °C or 600 MHz Bruker Instrument at 25 °C, using TMS as an internal standard, respectively. Multiplicity is tabulated as s for singlet, d for doublet, dd for doublet of doublet, t for triplet, and m for multiplet. The original spectra of the relative compounds could be found in Supplementary Materials. HRMS spectra were recorded on Finnigan-Mat-95 mass spectrometer, equipped with an ESI source. Experimental procedures for the preparation of compound 10 and Largazole are available in the reported literature [28].
3-(Tritylthio)propanal (3)
To a solution of triphenylmethyl mercaptan (1.38 g, 5.0 mmol, 1.0 equiv.) in CH2Cl2 (DCM, 30 mL) acrolein (0.393 g, 7.0 mmol, 1.4 equiv.) and triethylamine (0.98 mL, 7.0 mmol, 1.4 equiv.) was added, and the resulting mixture was stirred at room temperature for 1 h. Concentration in vacuo left aldehyde 3 as a white foamy solid. Rf = 0.13 [petroleum ether (PE)/ethyl acetate (EA) 40/1], 1H-NMR (400 MHz, CDCl3): δ 9.56 (brs, 1H), 7.23–7.43 (m, 15H), 2.47 (t, J = 7.0 Hz, 2H), 2.37 (t, J = 6.7 Hz, 2H).
Ethyl 2-fluoro-5-(tritylthio)pent-2-enoate (4)
To an anhydrous THF solution (30 mL) of PPh3 (3.15 g, 12.0 mmol, 4.0 equiv) and ethyl bromodifluoroacetate (0.83 mL, 6.0 mmol, 2.0 equiv), 1.0 M Et2Zn in hexane (12 mL, 12.0 mmol, 4.0 equiv) was rapidly added under argon. The mixture was stirred for 10 min (until the internal temperature returned to rt), then the aldehyde 3 (0.997 g, 3.0 mmol) was rapidly added. The mixture was stirred overnight. The resulting solution was then quenched with EtOH (15 mL), stirred for 15 min, and concentrated under reduced pressure. The residue was taken up in Et2O (100 mL) and filtered through Celite and then it was chromatographed (silica gel, PE/EA 40/1) to afford the ɑ-fluoroacrylate 4, with E-isomer (0.325 g, 26%) and Z-isomer (0.730 g, 58%), respectively, or afford 4 with a mixture of them (Z/E 3/1, determined by 19F NMR) in 97% yield.
For Z-4: Rf = 0.35 (PE/EA 40/1). 1H-NMR (400 MHz, CDCl3): δ 7.40 (m, 6H), 7.25 (m, 6H), 7.18 (m, 3H), 5.75 (dt, J = 20.9, 7.9 Hz, 1H), 4.23 (q, J = 7.1 Hz, 2H), 2.56 (m, 2H), 2.26 (t, J = 7.2 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H). 13C-NMR (150 MHz, CDCl3): δ 160.58 (d, 2JC-F = 34.5 Hz), 147.91 (d, 1JC-F = 252 Hz), 144.65, 129.48, 127.81, 126.60, 121.24 (d, 2JC-F = 19.6 Hz), 66.71, 61.28, 31.30, 24.55 (d, 3JC-F = 5.1 Hz), 14.00. 19F-NMR (376 MHz, CDCl3): δ –121.29 (d, J = 22.6 Hz). ESI-MS (m/z): 443.6 [M + Na]+. HRMS-ESI (m/z): [M + Na]+ calcd. for C26H25FO2SNa: 443.1452, found: 443.1452.
For E-4: Rf = 0.27 (PE/EA 40/1). 1H-NMR (400 MHz, CDCl3): δ 7.41 (m, 6H), 7.28 (m, 6H), 7.22 (m, 3H), 5.97 (dt, J = 32.8, 7.2 Hz, 1H), 4.25 (q, J = 7.1 Hz, 2H), 2.25 (m, 4H), 1.31 (t, J = 7.1 Hz, 3H). 13C-NMR (150 MHz, CDCl3): δ 155.83 (d, 2JC-F = 34.5 Hz), 143.62 (d, 1JC-F = 256.5 Hz), 139.93, 124.82, 123.19, 121.99, 113.57 (d, 2JC-F = 11.4 Hz), 62.15, 56.85, 25.79, 18.90, 9.39. 19F-NMR (376 MHz, CDCl3): δ –128.95 (d, J = 32.8 Hz). ESI-MS (m/z): 443.6 [M + Na]+. HRMS-ESI (m/z): [M + Na]+ calcd. for C26H25FO2SNa: 443.1452, found: 443.1454.
(Z)-2-Fluoro-5-(tritylthio)pent-2-enal (5)
To an anhydrous toluene solution (100 mL) of a mixture of Z-4 and E-4 prepared above (4.03 g, 9.58 mmol) 1.5 M DIBALH in toluene (22.4 mL, 33.5 mmol) was added dropwise under argon at −78 °C over 0.5 h. The mixture was stirred at −78 °C for 1 h, and the resulting solution was then quenched with MeOH (50 mL), and warmed to rt. After addition of the saturated aqueous solution of Rochelle salt, the mixture was stirred for overnight, and then the organic phase was separated. The aqueous phase was extracted with EA (100 mL × 2), and the combined organic extracts were dried, filtered, and concentrated in vacuo, and then it was chromatographed (silica gel, PE/DCM/EA 35/5/1) to afford the aldehyde 5 as a white foamy solid (3.10 g, 86%). Rf = 0.35 (PE/DCM/EA 35/5/1). 1H-NMR (400 MHz, CDCl3): δ 9.13 (d, J = 18.2 Hz, 1H), 7.43 (m, 6H), 7.27 (m, 9H), 5.75 (dt, J = 32.1, 7.2 Hz, 1H), 2.35 (m, 4H). 13C-NMR (100 MHz, CDCl3): δ 183.49 (d, 2JC-F = 24.9 Hz), 156.48 (d, 1JC-F = 261 Hz), 146.88, 144.53, 129.54, 128.71 (d, 2JC-F = 10.2 Hz), 127.99, 127.92, 127.29, 126.86, 67.09, 30.22, 24.01. 19F-NMR (376 MHz, CDCl3): δ −132.15 (dd, J = 32.1, 18.2 Hz). ESI-MS (m/z): 399.6 [M + Na]+. HRMS-ESI (m/z): [M + Na]+ calcd. for C24H21FOSNa: 399.1189, found: 399.1192.
(S/R,Z)-1-((R)-4-Benzyl-2-thioxothiazolidin-3-yl)-4-fluoro-3-hydroxy-7-(tritylthio)hept-4-en-1-one (8/9)
6 (1.12 g, 4.46 mmol) was dissolved in dry DCM (50 mL) and cooled to 0 °C. TiCl4 (0.82 mL, 7.43 mmol) was added dropwise. After stirring for 30 min, the resulting yellow suspension was cooled to −40 °C. i-Pr2NEt (1.32 mL, 7.97 mmol) was then added dropwise, and the reaction mixture was stirred for 2 h at this temperature. The resulting solution was then cooled to −90 °C. 5 (1.44 g, 3.71 mmol) was dissolved in dry DCM (20 mL) and added dropwise to the reaction mixture. The reaction mixture was stirred at −90 °C for 3 h and quenched by the addition of a saturated aqueous solution of NH4Cl. The reaction mixture was then allowed to warm to room temperature and extracted three times with DCM (20 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and the solvent evaporated under reduced pressure. The resulting crude was purified by flash chromatography on silica gel, eluting with PE/EA (8/1) to afford 8 (1.33 g, 59%) and 9 (0.656 g, 29%) as yellow oils, respectively.
For 8: Rf = 0.19 (PE/EA 4/1). [α]20D: −78.0 (c 3.7, CHCl3). 1H-NMR (400 MHz, CDCl3): δ 7.29 (m, 20H), 5.33 (m, 1H), 4.86 (dd, J = 36.8, 7.1 Hz, 1H), 4.63 (brs, 1H), 3.67 (m, 1H), 3.47 (dd, J = 17.9, 8.8 Hz, 1H), 3.36 (dd, J = 11.2, 7.2 Hz, 1H), 3.21 (m, 1H), 3.03 (m, 1H), 2.95 (d, J = 4.1 Hz, 1H), 2.87 (d, J = 11.6 Hz, 1H), 2.19 (m, 4H). 13C-NMR (150 MHz, CDCl3): δ 201.27, 172.02, 158.60 (d, 1JC-F = 257.2 Hz), 144.87, 136.32, 129.60, 129.45, 128.97, 127.88, 127.34, 126.63, 104.96 (d, 2JC-F = 12.9 Hz), 68.32, 66.63, 42.81, 36.79, 32.18, 31.52, 22.72. 19F-NMR (376 MHz, CDCl3): δ –129.15 (dd, J = 32.1, 18.2 Hz). ESI-MS (m/z): 650.4 [M + Na]+. HRMS-ESI (m/z): [M + Na]+ calcd. for C36H34FNO2S3Na: 650.1628, found: 650.1621.
For 9: Rf = 0.30 (PE/EA 4/1). [α]20D: −65.4 (c 0.30, CHCl3). 1H-NMR (400 MHz, CDCl3): δ 7.30 (m, 20H), 5.37 (m, 1H), 4.85 (dt, J = 37.2, 7.0 Hz, 1H), 4.56 (brs, 1H), 3.75 (dd, J = 17.5, 9.2 Hz, 1H), 3.41 (m, 2H), 3.21 (m, 2H), 3.03 (dd, J = 13.2, 10.4 Hz, 1H), 2.89 (d, J = 11.6 Hz, 1H), 2.19 (m, 4H). 13C-NMR (150 MHz, CDCl3): δ 201.27, 172.02, 158.60 (d, 1JC-F = 257.2 Hz), 144.87, 136.32, 129.60, 129.45, 128.97, 127.88, 127.34, 126.63, 104.96 (d, 2JC-F = 12.9 Hz), 68.32, 66.63, 42.81, 36.79, 32.18, 31.52, 22.72. ESI-MS (m/z): 650.4 [M + Na]+. HRMS-ESI (m/z): [M + Na]+ calcd. for C36H34FNO2S3Na: 650.1628, found: 650.1621.
(R)-Methyl 2′-(((S/R,Z)-4-fluoro-3-hydroxy-7-(tritylthio)hept-4-enamido)methyl)-4-methyl-4,5-dihydro-[2,4′-bithiazole]-4-carboxylate (31S/31R) (11)
To a stirring solution of 10 (0.459 g, 1.28 mmol) and DMAP (0.408 g, 3.34 mmol) in anhydrous DCM (20 mL) a solution of 8 (0.820 g, 1.28 mmol) in DCM (20 mL) was added dropwise at rt, and the resultant solution was stirred for another 2 h. The solution was then quenched with NH4Cl saturated solution (20 mL) and separated, and the aqueous phase was extracted with DCM (30 mL × 3). The combined organic phase was washed successively with H2O, brine, dried with Na2SO4 and filtered. After removal of the solvent, the residue was purified by flash chromatography on silica gel with DCM/EA (2/1) to yield 11 (0.600 g, 70%) as a foamy solid.
Rf = 0.26 (PE/EA 1/1). [α]20D: −32.2 (c 3.6, CHCl3). 1H-NMR (400 MHz, CDCl3): δ 7.89 (s, 1H), 4.79 (m, 2H), 4.68 (m, 2H), 4.49 (brs, 1H), 3.87 (d, J = 11.4 Hz, 1H), 3.79 (s, 3H), 3.27 (d, J = 11.4 Hz, 1H), 2.56 (m, 2H), 2.15 (m, 5H), 1.63 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ 173.62, 171.49, 167.63, 162.78, 158.92 (d, 1JC-F = 257.4 Hz), 148.20, 144.83, 129.58, 127.91, 126.67, 122.56, 104.67 (d, 2JC-F = 12.3 Hz), 84.49, 66.97 (d, 2JC-F = 33 Hz), 66.62, 53.01, 41.54, 40.80, 39.72, 31.49, 24.02, 22.70 (d, 3JC-F = 3.5 Hz). 19F-NMR (376 MHz, CDCl3): δ −124.95 (dd, J = 36.2, 20.3 Hz). ESI-MS (m/z): 712.4 [M + Na]+. HRMS-ESI (m/z): [M + Na]+ calcd. for C36H36FN3O4S3Na: 712.1744, found: 712.1748.
(R)-Methyl 2′-((5S/R,8S)-1-(9H-fluoren-9-yl)-8-((Z)-1-fluoro-4-(tritylthio)but-1-en-1-yl)-5-isopropyl-3,6,10-trioxo-2,7-dioxa-4,11-diazadodecan-12-yl)-4-methyl-4,5-dihydro-[2,4′-bithiazole]-4-carboxylate (13a)
To a solution of Fmoc-Val-OH (0.165 g, 0.49 mmol) and DMAP (0.005 g, 0.041 mmol) in DCM (15 mL) 2,4,6-trichlorobenzoyl chloride (0.089 mL, 0.568 mmol) was added at 0 °C, and then the solution continued to stirred for 1 h. Then. a solution of 11 and DIPEA (0.11 mL, 0.65 mmol) in DCM (10 mL) was added to the stirring mixture. The reaction was allowed to warm to rt and stirred for 1 h. This solution was quenched with a NH4Cl aqueous solution and separated. The aqueous phase was extracted with DCM (30 mL × 3) and the combined organic phase was washed successively with H2O, brine, dried with Na2SO4 and filtered. After the removal of the solvent, the resulting crude was purified by flash chromatography on silica gel, eluting with PE/EA (5/4) to afford 13a (0.266 g, 65%) as a white foamy solid. Rf = 0.26 (PE/EA 1/1). [α]20D: −16.4 (c 0.34, CHCl3). 1H-NMR (600 MHz, CDCl3): δ 7.89 (s, 1H), 7.75 (d, J = 7.2 Hz, 2H), 7.57 (d, J = 3.6 Hz, 2H), 7.38 (m, 8H), 7.34–7.24 (m, 8H), 7.20 (t, J = 7.1 Hz, 3H), 6.64 (brs, 1H), 5.67–5.79 (m, 1H), 5.25 (brs, 1H), 4.92 (dt, J = 35.9, 7.0 Hz, 1H), 4.68 (m, 2H), 4.37 (m, 2H),4.20 (t, J = 6.9 Hz, 1H), 4.16 (dd, J = 7.6, 5.8 Hz, 1H), 3.85 (d, J = 11.3 Hz, 1H), 3.78 (s, 3H), 3.24 (d, J = 11.3 Hz, 1H), 2.70 (m, 2H), 2.01–2.24 (m, 5H), 1.63 (s, 3H), 0.88 (t, J = 6.5 Hz, 3H), 0.83 (d, J = 6.6 Hz, 3H). 13C-NMR (150 MHz, CDCl3): δ 173.62, 170.92, 168.24, 167.81, 162.77, 156.29, 153.75 (d, 1JC-F = 257.4 Hz), 148.35, 144.78, 143.79 (d, JC-F = 19.3 Hz), 141.33, 129.58, 127.91, 127.82 (d, JC-F = 24.5 Hz), 127.12, 126.68, 125.08, 122.33, 120.00, 109.63 (d, 2JC-F = 12.0 Hz), 84.56, 69.62 (d, 3JC-F = 28.5 Hz), 67.08, 66.71, 59.17, 52.91, 47.19, 41.53, 41.09, 38.02, 31.59, 31.10 (d, J = 10.2 Hz), 23.98, 22.79, 22.66, 18.81, 17.71. 19F NMR (376 MHz, CDCl3): δ −125.77 (dd, J = 35.4, 21.1 Hz). ESI-MS (m/z): 1011.2 [M + H]+. HRMS-ESI (m/z): [M+Na]+ calcd. for C56H55FN4O7S3Na: 1033.3109, found: 1033.3102.
For 13b: 60%, Rf = 0.26 (PE/ EA 1/1). [α]20D: −4.7 (c = 0.097, CHCl3). 1H-NMR (600 MHz, CDCl3) δ 7.89 (s, 1H), 7.76 (d, J = 7.5 Hz, 2H), 7.53 (t, J = 7.2 Hz, 2H), 7.39 (d, J = 7.4 Hz, 8H), 7.33–7.25 (m, 9H), 7.19 (dd, J = 16.7, 7.7 Hz, 6H), 7.04 (d, J = 6.9 Hz, 2H), 6.60 (s, 1H), 5.77–5.57 (m, 1H), 5.26 (d, J = 7.5 Hz, 1H), 4.81 (dt, J = 36.0, 7.0 Hz, 1H), 4.70–4.61 (m, 2H), 4.52 (dd, J = 12.9, 6.3 Hz, 1H), 4.45–4.27 (m, 2H), 4.18 (t, J = 6.8 Hz, 1H), 3.86 (d, J = 11.3 Hz, 1H), 3.78 (s, 3H), 3.25 (d, J = 11.3 Hz, 1H), 3.03 (m, 2H), 2.66 (m, 2H), 2.18 (t, J = 6.5 Hz, 3H), 2.15–2.07 (m, 2H), 1.63 (s, 4H). 13C-NMR (150 MHz, CDCl3) δ 172.56, 169.70, 167.54, 167.03, 162.15, 154.99 (d, J = 11.5 Hz), 154.46 (d, J = 14.7 Hz), 152.56 (d, J = 74.3 Hz), 147.53 (d, J = 54.5 Hz), 144.14, 143.09 (d, J = 14.9 Hz), 140.69, 134.75, 128.94, 128.73, 127.94, 127.29, 127.11, 126.50 (d, J = 7.5 Hz), 126.07, 124.44 (d, J = 7.6 Hz), 121.71, 119.37, 109.04 (d, J = 12.3 Hz), 83.92, 69.32 (d, J = 29.3 Hz), 66.25 (d, J = 46.7 Hz), 54.26, 52.28, 46.50, 40.89, 40.41, 37.41, 37.18, 30.43, 23.36, 22.31. 19F-NMR (376 MHz, CDCl3): δ −126.27 (dd, J = 35.4, 21.1 Hz). ESI-MS (m/z): 1059.2 [M + H]+. HRMS-ESI (m/z): [M + Na]+ calcd. for C60H55FN4O7S3Na:1081.3109, found: 1081.3126.
(5R,8S,11S/R)-11-((Z)-1-Fluoro-4-(tritylthio)but-1-en-1-yl)-8-isopropyl-5-methyl-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.12,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione (14a)
To a solution of 13a (0.420 g, 0.42 mmol) in THF/H2O (4/1, v/v, 20 mL) LiOH∙H2O (0.027 g, 0.63 mmol) was added at 0 °C, and the reaction mixture was stirred for 3 h at that temperature. After the hydrolysis was completed, the reaction mixture was quenched with 1.0 M HCl aqueous solution (1.0 mL), and then extracted with DCM (20 mL × 3). The combined organic layers were washed successively with water, brine, dried with Na2SO4 and filtered. After evaporation, the residue was purified by flash chromatography on silica gel, eluting with DCM/MeOH (40/1 to 10/1) to afford the resultant acid (0.251 g) as a white foamy solid.
The resultant acid (0.251 g) was dissolved in dry DCM (20 mL), and Et2NH (1.0 mL) was added at rt. After stirring for 3 h and removal of the solvent, toluene (10 mL) was added and evaporated under reduced pressure, and this operation was repeated three times to remove the remaining Et2NH, affording the crude product.
Then, the crude amino acid was dissolved in dry DCM (100 mL), and the solution was added dropwise to a stirring solution of HATU (0.380 g, 1.0 mmol), HOAT (0.136 g, 1.0 mmol), and DIPEA (0.33 mL, 2.0 mmol) in DCM (300 mL) at rt. The reaction mixture was stirred at rt for 12 h. The solution was concentrated under reduced pressure, and this resultant solution (100 mL) was washed with saturated NH4Cl solution, water, and brine, successively, dried over Na2SO4, and filtered. After removal of the solvent, the residue was purified by flash chromatography on silica gel, eluting with PE/EA/MeOH (20/20/8) to afford 14a (31%, over three steps) as a white foamy solid. Rf = 0.15 (PE/EA 2/3). [α]20D −14.3 (c 0.4, CHCl3). 1H-NMR (600 MHz, CDCl3): δ 7.76 (s, 1H), 7.29 (m, 15H), 7.13 (d, J = 9.2 Hz, 1H), 6.41 (d, J = 7.6 Hz, 1H), 5.60 (dd, J = 20.2, 10.5 Hz, 1H), 5.29 (dd, J = 17.5, 9.7 Hz, 1H), 5.00 (m, 1H), 4.62 (d, J = 7.6 Hz, 1H), 4.20 (d, J = 18.1 Hz, 1H), 4.04 (d, J = 11.0 Hz, 1H), 3.28 (d, J = 11.3 Hz, 1H), 3.12 (m, 1H), 2.70 (d, J = 16.6 Hz, 1H), 2.15 (m, 5H), 1.85 (s, 3H), 0.68 (d, J = 6.4 Hz, 3H), 0.49 (d, J = 6.6 Hz, 3H). 13C-NMR (150 MHz, CHCl3): δ 173.60, 168.94, 168.76, 167.89, 164.58, 155.25 (d, 1JC-F = 256 Hz), 147.49, 129.58, 127.91, 126.65, 124.33, 109.26 (d, 2JC-F = 12.4 Hz), 84.39, 69.95 (d, 3JC-F = 29.6 Hz), 57.58, 43.32, 41.13, 38.63, 37.49, 34.23, 31.12, 29.72, 24.13, 22.88, 18.84, 16.57, 14.22. 19F NMR (376 MHz, CDCl3): δ –124.95 (dd, J = 36.2, 20.3 Hz). ESI-MS (m/z): 779.4 [M + Na]+. HRMS-ESI (m/z): [M + Na]+ calcd. for C40H41FN4O4S3Na: 779.2166, found: 779.2171.
For 14b: 22%, Rf = 0.15 (PE/EA 2/3). [α]20D: + 28.6 (c 0.021, CHCl3), 1H-NMR (600 MHz, CDCl3) δ 7.61 (s, 1H), 7.38 (d, J = 7.6 Hz, 6H), 7.27 (dd, J = 11.0, 4.3 Hz, 6H), 7.20 (t, J = 7.3 Hz, 3H), 7.13 (d, J = 7.7 Hz, 1H), 6.94–6.70 (m, 5H), 6.15 (d, J = 8.3 Hz, 1H), 5.71 (m, J = 18.9, 10.1, 1.9 Hz, 1H), 5.05 (d, 12 Hz, 1H), 5.00 (dt, 36 Hz, 7.5Hz, 1H), 4.88 (m, 1H), 4.17 (dd, J = 17.4, 2.8 Hz, 1H), 4.08 (d, J = 11.3 Hz, 1H), 3.25 (d, J = 11.3 Hz, 1H), 3.20 (dd, J = 14.0, 23 Hz, 1H), 3.06 (dd, J = 14.0, 5.9 Hz, 1H), 2.99 (dd, J = 16.4, 10.2 Hz, 1H), 2.62 (dd, J = 16.4, 2.1 Hz, 1H), 2.17 (dt, J = 11.0, 4.0 Hz, 2H), 2.10 (dt, J = 14.4, 7.2 Hz, 2H), 1.79 (s, 3H). 13C-NMR (150 MHz, CDCl3): δ 173.67, 168.89, 168.16, 166.97, 163.73, 155.33, 153.63, 147.26, 144.78, 135.11, 129.60 (d, J = 8.8 Hz), 127.88 (d, J = 7.6 Hz), 126.65, 125.93, 123.68, 109.17 (d, J = 12.5 Hz), 84.19, 70.18 (d, J = 30.9 Hz), 66.61, 54.19, 42.46, 40.98, 37.70, 37.46, 31.12, 24.98, 22.88 (d, J = 3.8 Hz). 19F-NMR (376 MHz, CDCl3): δ –124.43 (dd, J = 36.2, 20.3 Hz). ESI-MS (m/z): 827.2 [M + Na]+. HRMS-ESI (m/z): [M + Na]+ calcd. for C44H41FN4O4S3Na: 827.2166, found: 827.2166.
(5R,8S,11S/R)-11-((Z)-1-Fluoro-4-mercaptobut-1-en-1-yl)-8-isopropyl-5-methyl-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.12,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione (15a)
14a (50 mg, 0.066 mmol) was dissolved in dry DCM (15 mL) and cooled to 0 °C. The mixture was successively treated with Et3SiH (27 µL, 0.13 mmol) and TFA (0.30 mL, 4.0 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 1.5 h before being concentrated and chromatographed (EtOAc) to provide a clear oil (15 mg, 0.03 mmol). The reaction was quenched with a saturated NaHCO3 solution (10 mL) and separated. The aqueous phase was extracted with DCM (10 mL × 3), and the combined layers were washed with brine, dried over Na2SO4, and filtered. After removal of the solvent, the residue was purified by flash chromatography on silica gel, eluting with DCM/EA (1/1) to afford 15a in 67% yield as a white foamy solid. Rf = 0.42 (PE/EA 2/3). 1H-NMR (600 MHz, CDCl3): δ 7.78 (s, 1H), 7.14 (d, J = 9.5 Hz, 1H), 6.51 (d, J = 7.3 Hz, 1H), 5.67 (dd, J = 20.2, 11.0 Hz, 1H), 5.32 (dd, J = 17.5, 9.7 Hz, 2H), 5.15 (dt, J = 36.5, 7.5 Hz, 1H), 4.65 (dd, J = 9.4, 3.2 Hz, 1H), 4.26 (dd, J = 17.5, 2.8 Hz, 1H), 4.05 (d, J = 11.4 Hz, 1H), 3.30 (d, J = 11.4 Hz, 1H), 3.17 (m, 2H), 2.76 (d, J = 16.4 Hz, 1H), 2.56 (m, 3H), 2.42 (m, 2H), 2.15 (m, 5H), 1.87 (s, 3H), 0.69 (d, J = 6.9 Hz, 3H), 0.50 (d, J = 6.8 Hz, 3H). ESI-MS (m/z): 515.2 [M + H]+. HRMS-ESI (m/z): [M + H]+ calcd. for C21H27FN4O4S3H: 515.1251, found: 515.1252.
For 15b: 59%, Rf = 0.42 (PE/ EA 2/3). 1H-NMR (600 MHz, CDCl3) δ 7.66 (s, 1H), 7.19 (m, 2H), 6.84 (m, 5H), 6.15 (s, 1H), 5.78 (dd, J = 17.9, 9.4 Hz, 1H), 5.16 (dt, J = 36.3, 7.5 Hz, 1H), 5.04 (dd, J = 17.4, 8.2 Hz, 1H), 4.93 (m, 1H), 4.27 (d, J = 17.1 Hz, 1H), 4.11 (d, J = 11.2 Hz, 1H), 3.26 (d, J = 11.3 Hz, 1H), 3.22 (dd, J = 14.0, 3.0 Hz, 1H), 3.12–3.08 (m, 1H), 3.07 (d, J = 5.9 Hz, 1H), 2.67 (d, J = 14.8 Hz, 1H), 2.54 (dd, J = 14.4, 7.1 Hz, 1H), 2.40 (m, 2H), 1.83 (s, 3H). ESI-MS (m/z): 563.0 [M + H]+. HRMS-ESI (m/z): [M + H]+ calcd. for C25H27FN4O4S3H: 563.1251, found: 563.1254.
S-((Z)-4-Fluoro-4-((5R,8S,11S/R)-8-isopropyl-5-methyl-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.12,5]icosa-1(18),2(20),16(19)-trien-11-yl)but-3-en-1-yl) octanethioate (16a)
The free thiol 15a (26 mg) was dissolved in dry DCM (10 mL) and cooled to 0 °C. The mixture was successively treated with Et3N (14 µL, 0.1 mmol) and octanoyl chloride (42 µL, 0.25 mmol). The reaction was allowed to warm to rt and stirred for 2 h, and then quenched with a saturated NaHCO3 solution (10 mL) and separated. The aqueous phase was extracted with DCM (10 mL × 3), and the combined layers were washed successively with brine, dried over Na2SO4, and filtered. After removal of the solvent, the residue was purified by flash chromatography on silica gel, eluting with DCM/EA (1/1) to afford 16a (61%) as a white foamy solid. Rf = 0.42 (DCM/EA 3/1). [α]20D: +34.3 (c 0.3, CHCl3). 1H-NMR (600 MHz, CDCl3): δ 7.78 (s, 1H), 7.13 (d, J = 9.5 Hz, 1H), 6.42 (d, J = 7.8 Hz, 1H), 5.65 (m, 1H), 5.32 (dd, J = 17.5, 9.8 Hz, 1H), 5.10 (dt, J = 7.2, 2 Hz, 1H), 4.65 (dd, J = 9.3, 2.9 Hz, 1H), 4.26 (dd, J = 17.5, 2.8 Hz, 1H), 4.05 (d, J = 11.3 Hz, 1H), 3.28 (d, J = 11.3 Hz, 1H), 3.16 (dd, J = 16.4, 11.4 Hz, 1H), 2.90 (t, J = 7.1 Hz, 2H), 2.74 (d, J = 14.8 Hz, 1H), 2.54 (t, J = 7.5 Hz, 2H), 2.37 (m, 2H), 2.13 (m, 1H), 1.88 (s, 3H), 1.65 (m, 2H), 1.28 (m, 8H), 0.88 (m, 3H), 0.68 (d, J = 6.7 Hz, 3H), 0.49 (d, J = 6.7 Hz, 3H). 13C-NMR (150 MHz, CDCl3): δ 199.35, 173.64, 168.96, 168.84, 167.90, 164.62, 155.25 (d, J = 256 Hz), 147.49, 124.41, 108.71 (d, J = 12.6 Hz), 84.40, 69.95 (d, J = 29.6 Hz), 57.54, 44.17, 43.35, 41.17, 37.47, 34.33, 31.63, 28.92, 27.9, 25.64, 24.13, 23.86, 22.61, 18.86, 16.51, 14.09. 19F NMR (376 MHz, CDCl3): δ −124.76 (dd, J = 35.9, 20.9 Hz). ESI-MS (m/z): 663.3 [M + Na]+. HRMS-ESI (m/z): [M + Na]+ calcd. for C40H41FN4O4S3Na: 663.2115, found: 663.2139.
For 16b: 66%, Rf = 0.42 (DCM/EA 3/1). [α]20D: +36.6 (c 0.025, CHCl3). 1H-NMR (150 MHz, CDCl3) δ 7.64 (s, 1H), 7.14 (d, J = 7.7 Hz, 2H), 7.00–6.74 (m, 5H), 6.15 (d, J = 8.0 Hz, 1H), 5.76 (dd, J = 19.2, 9.9 Hz, 1H), 5.12 (dt, J = 36.3Hz, 7.5 Hz, 1H), 5.06 (d, J = 9.0 Hz, 1H), 4.92 (t, J = 8.1 Hz, 1H), 4.92 (t, J = 8.1 Hz, 1H), 4.24 (dd, J = 17.4, 2.1 Hz, 1H), 4.10 (d, J = 11.2 Hz, 1H), 3.23 (d, J = 11.2 Hz, 1H), 3.21 (d, J = 2.8 Hz, 1H), 3.06 (m, 2H), 2.88 (t, J = 7.1 Hz, 2H), 2.66 (d, J = 16.0 Hz, 1H), 2.53 (t, J = 7.5 Hz, 2H), 2.36 (dd, J = 14.4, 7.2 Hz, 2H), 1.83 (s, 3H), 1.64 (dd, J = 14.0, 7.0 Hz, 3H), 1.27 (m, 8H), 0.89 (dd, J = 9.0, 4.6 Hz, 3H). 13C-NMR (150 MHz, CDCl3): δ 198.61, 173.12, 168.27, 167.47, 166.35, 163.04, 146.63 (d, J = 28.5 Hz), 134.52, 129.03, 127.22, 125.29, 123.03, 107.82 (d, J = 23.4 Hz), 83.63, 69.52 (d, J = 30.9 Hz), 53.57, 43.52, 41.84, 40.37, 37.00 (d, J = 18.3 Hz), 30.98, 29.07, 28.27, 27.27, 24.99, 24.35, 23.20, 21.95, 13.45 (d, J = 8.6 Hz). 19F-NMR (376 MHz, CDCl3): δ −124.76 (dd, J = 36.1, 19.3 Hz). ESI-MS (m/z): 689.2 [M + H]+. HRMS-ESI (m/z): [M + H]+ calcd. for C33H41FN4O5S3: 689.2296, found: 689.2302.

3.2. Biological Evaluation

3.2.1. Recombinant Human HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 Enzymatic Assays

The assays were carried out by Shanghai ChemPartner Co., Ltd. (Shanghai, China). Briefly, different concentrations of compounds were incubated with recombinant human HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 (BPS Biosciences, San Diego, CA, USA) at room temperature for 15 min, which was followed by adding Ac-peptide-AMC substrates to initiate the reaction in Tris-based assay buffer. Reaction mixtures were incubated at room temperature for 60 min in the HDAC1, HDAC2, HDAC3, and HDAC6 assays, and were incubated for 240 min in the HDAC8 assay. Then a stop solution containing trypsin was added. The coupled reaction was incubated for another 90 min at 37 °C. Fluorescent AMC released from substrate was measured in SynergyMx (BioTek, Winooski, VT, USA) using filter sets as excitation = 355 nm and emission = 460 nm. IC50 values were calculated by GraphPad Prism version 4.00 Windows (GraphPad Software, San Diego, CA, USA).

3.2.2. Cytotoxic Effect Tested by 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) Assay

The MTT assay was used to determine the cytotoxic effect of these compounds on A549, HCT116, MDA-MB-231, and SK-OV-3 tumor cells. Cells (600,000 cells/well) were seeded in 96-well plates and incubated for 24 h before being treated with various concentrations of compounds or solvent control. Cells were further incubated for 72 h and then treated with MTT and incubated for another 3 h. The media were then removed and 100 µL DMSO was added to each well. The absorbance at 550 nm was measured by a SpectraMAX340 microplate reader (Molecular Devices, Sunnyvale, CA, USA) with a reference wavelength at 690 nm. Largazole was used as a positive control in the assay.

4. Conclusions

Largazole and Psammaplin A, two marine natural products belonging to a family of sulfur-containing natural products with potent HDAC inhibitory activities, contain the similar side chain unit. Inspired by the structural similarity, we hypothesized the fluoro olefin moiety would mimic both the alkene moiety in Largazole and amide moiety in Psammaplin A, and thus designed and synthesized two novel fluoro olefin analogs of Largazole. The preliminary biological assays showed that the fluoro analogs possessed comparable Class I HDAC inhibitory activities, indicating that this kind of modification on the side chain of Largazole was tolerable.

Supplementary Materials

The supporting information is available online at https://www.mdpi.com/1660-3397/17/6/333/s1.

Author Contributions

B.Z. and G.S. performed the chemical research and analyzed the data. X.Y., Z.-W.R. and Y.L. participated in the research. X.L. was responsible for the funding of project, the design of the research and the writing of the manuscript. All authors read and approved the final manuscript.

Funding

This research was funded by National Key Research and Development Program of China (No. 2018YFC0310906) and National Natural Science Foundation of China (No. 21472024 and No. 21242008).

Acknowledgments

The authors acknowledge National Key Research and Development Program of China and National Natural Science Foundation of China for the financial support. The authors also acknowledge Tan Wen-Fu for the cellular assays and Shanghai ChemPartner Co., Ltd. for the HDAC inhibition assays. The authors are grateful to Jie-Fei Cheng for his helpful discussion.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Delcuve, G.P.; Khan, D.H.; Davie, J.R. Roles of histone deacetylases in epigenetic regulation: Emerging paradigms from studies with inhibitors. Clin. Epigenet. 2012, 4, 5–17. [Google Scholar] [CrossRef] [PubMed]
  2. De Ruijter, A.J.; Van Gennip, A.H.; Caron, H.N.; Kemp, S.; Van Kuilenburg, A.B. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem. J. 2003, 370, 737–749. [Google Scholar] [CrossRef] [PubMed]
  3. Johnstone, R.W. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 2002, 1, 287–299. [Google Scholar] [CrossRef] [PubMed]
  4. Emanuele, S.; Lauricella, M.; Tesoriere, G. Histone deacetylase inhibitors: Apoptotic effects and clinical implications. Int. J. Oncol. 2008, 33, 637–646. [Google Scholar] [CrossRef] [PubMed]
  5. Roche, J.; Bertrand, P. Inside HDACs with more selective HDAC inhibitors. Eur. J. Med. Chem. 2016, 121, 451–483. [Google Scholar] [CrossRef] [PubMed]
  6. Balasubramanian, S.; Verner, E.; Buggy, J.J. Isoform-specific histone deacetylase inhibitors: The next step? Cancer Lett. 2009, 280, 211–221. [Google Scholar] [CrossRef] [PubMed]
  7. Tabackman, A.A.; Frankson, R.; Marsan, E.S.; Perry, K.; Cole, K.E. Structure of ‘linkerless’ hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket. J. Struct. Biol. 2016, 195, 373–378. [Google Scholar] [CrossRef] [PubMed]
  8. Taori, K.; Paul, V.J.; Luesch, H. Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J. Am. Chem. Soc. 2008, 130, 1806–1807. [Google Scholar] [CrossRef] [PubMed]
  9. Ying, Y.; Taori, K.; Kim, H.; Hong, J.; Hendrik Luesch, H. Total Synthesis and Molecular Target of Largazole, a Histone Deacetylase Inhibitor. J. Am. Chem. Soc. 2008, 130, 8455–8459. [Google Scholar] [CrossRef]
  10. Bowers, A.; West, N.; Taunton, J.; Schreiber, S.L.; Bradner, J.E.; Williams, R.M. Thiophene-derivatized Fluorescent Benzamides as Possible Probes for Histone Deacetylases. J. Am. Chem. Soc. 2008, 130, 11219–11222. [Google Scholar] [CrossRef]
  11. Maolanon, A.R.; Kristensen, H.M.E.; Leman, L.J.; Ghadiri, M.R.; Olsen, C.A. Natural and synthetic macrocyclic inhibitors of the histone deacetylase enzymes. ChemBioChem 2017, 18, 5–49. [Google Scholar] [CrossRef]
  12. Reddy, D.N.; Ballante, F.; Chuang, T.; Pirolli, A.; Marrocco, B.; Marshall, G.R. Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors. J. Med. Chem. 2016, 59, 1613–1633. [Google Scholar] [CrossRef] [PubMed]
  13. Yao, Y.; Tu, Z.; Liao, C.; Wang, Z.; Li, S.; Yao, H.; Li, Z.; Jiang, S. Discovery of novel class I histone deacetylase inhibitors with promising in vitro and in vivo antitumor activities. J. Med. Chem. 2015, 58, 7672–7680. [Google Scholar] [CrossRef] [PubMed]
  14. Clausen, D.J.; Smith, W.B.; Haines, B.E.; Wiest, O.; Bradner, J.E.; Williams, R.M. Modular synthesis and biological activity of pyridyl-based analogs of the potent Class i Histone Deacetylase Inhibitor Largazole. Bioorg. Med. Chem. 2015, 23, 5061–5074. [Google Scholar] [CrossRef] [PubMed]
  15. Ueda, H.; Nakajima, H.; Hori, Y.; Fujita, T.; Nishimura, M.; Goto, T.; Okuhara, M.J. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci. Biotechnol. Biochem. 1994, 58, 1579–1583. [Google Scholar] [CrossRef] [PubMed]
  16. Shigematsu, N.; Ueda, H.; Takase, S.; Tanaka, H.J. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. J. Antibiot. 1994, 47, 311–314. [Google Scholar] [CrossRef] [PubMed]
  17. Ueda, H.; Manda, T.; Matsumoto, S.; Mukumoto, S.; Nishigaki, F.; Kawamura, I.; Shimomura, K.J. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J. Antibiot. 1994, 47, 315–323. [Google Scholar] [CrossRef]
  18. Masuoka, Y.; Nagai, A.; Shin-ya, K.; Furihata, K.; Nagai, K.; Suzuki, K.; Hayakawa, Y.; Seto, H. Spiruchostatins A and B, novel gene expression-enhancing substances produced by Pseudomonas sp. Tetrahedron Lett. 2001, 42, 411–444. [Google Scholar] [CrossRef]
  19. Baud, M.G.J.; Leiser, T.; Haus, P.; Samlal, S.; Wong, A.C.; Wood, R.J.; Petrucci, V.; Gunaratnam, M.; Hughes, S.M.; Buluwela, L.; et al. Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets. Med. Chem. 2012, 55, 1731–1750. [Google Scholar] [CrossRef]
  20. Poli, G.; Fabio, R.D.; Ferrante, L.; Summa, V.; Botta, M. Largazole Analogues as Histone Deacetylase Inhibitors and Anticancer Agents: An Overview of Structure–Activity Relationships. ChemMedChem 2017, 12, 1917–1926. [Google Scholar] [CrossRef]
  21. Ying, Y.; Liu, Y.; Byeon, S.R.; Kim, H.; Luesch, H.; Hong, J. Synthesis and activity of largazole analogues with linker and macrocycle modification. Org. Lett. 2008, 10, 4021–4024. [Google Scholar] [CrossRef] [PubMed]
  22. Zeng, X.; Yin, B.; Hu, Z.; Liao, C.; Liu, J.; Li, S.; Li, Z.; Nicklaus, M.C.; Zhou, G.; Jiang, S. Total synthesis and biological evaluation of largazole and derivatives with promising selectivity for cancers cells. Org. Lett. 2010, 12, 1368–1371. [Google Scholar] [CrossRef] [PubMed]
  23. Bowers, A.A.; West, N.; Newkirk, T.L.; Troutman-Youngman, A.E.; Schreiber, S.L.; Wiest, O.; Bradner, J.E.; Williams, R.M. Synthesis and histone deacetylase inhibitory activity of largazole analogs: Alteration of the zinc-binding domain and macrocyclic scaffold. Org. Lett. 2009, 11, 1301–1304. [Google Scholar] [CrossRef] [PubMed]
  24. Bhansali, P.; Hanigan, C.L.; Casero, R.A.; Tillekeratne, L.M. Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: Synthesis and biological evaluation. J. Med. Chem. 2011, 54, 7453–7463. [Google Scholar] [CrossRef] [PubMed]
  25. Kim, B.; Park, H.; Salvador, L.A.; Serrano, P.E.; Kwan, J.C.; Zeller, S.L.; Chen, Q.Y.; Ryu, S.; Liu, Y.; Byeon, S.; et al. Evaluation of class I HDAC isoform selectivity of largazole analogues. Bioorg. Med. Chem. Lett. 2014, 24, 3728–3731. [Google Scholar] [CrossRef] [Green Version]
  26. Kim, B.; Ratnayake, R.; Lee, H.; Shi, G.; Zeller, S.L.; Li, C.; Luesch, H.; Hong, J. Synthesis and biological evaluation of largazole zinc-binding group analogs. Bioorg. Med. Chem. 2017, 25, 3077–3086. [Google Scholar] [CrossRef]
  27. Cole, K.E.; Dowling, D.P.; Boone, M.A.; Phillips, A.J.; Christianson, D.W. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases. J. Am. Chem. Soc. 2011, 133, 12474–12477. [Google Scholar] [CrossRef]
  28. Yu, X.; Zhang, B.; Shan, G.; Wu, Y.; Yang, F.-L.; Lei, X. Synthesis of the molecular hybrid inspired by Largazole and Psammaplin A. Tetrahedron 2018, 74, 549–555. [Google Scholar] [CrossRef]
  29. Couve-Bonnaire, S.; Cahard, D.; Pannecoucke, X. Chiral dipeptide mimics possessing a fluoroolefin moiety: A relevant tool for conformational and medicinal studies. Org. Biomol. Chem. 2007, 5, 1151–1157. [Google Scholar] [CrossRef]
  30. Zoute, L.; Dutheuil, G.; Quirion, J.C.; Jubault, P.; Pannecoueke, X. Efficient Synthesis of Fluoroalkenes via Diethylzinc-Promoted Wittig Reaction. Synthesis 2006, 2006, 3409–3418. [Google Scholar] [CrossRef]
  31. Nagao, Y.; Hagiwara, Y.; Kumagai, T.; Ochiai, M.; Inoue, T.; Hashimoto, K.; Fujita, E. New C4-Chiral l,3-Thiazolidine-2-thiones: Excellent Chiral Auxiliaries for Highly Diastereocontrolled Aldol-Type Reactions of Acetic Acid and α,β-Unsaturated Aldehydes. J. Org. Chem. 1986, 51, 2391–2393. [Google Scholar] [CrossRef]
  32. Xiao, Q.; Wang, L.-P.; Jiao, X.-Z.; Liu, X.-Y.; Wu, Q.; Xie, P. Concise total synthesis of largazole. J. Asian Nat. Prod. Res. 2010, 12, 940–949. [Google Scholar] [CrossRef] [PubMed]
  33. Chen, F.; Chai, H.; Su, M.-B.; Zhang, Y.-M.; Li, J.; Xie, X.; Nan, F.-J. Potent and orally efficacious bisthiazole-based histone deacetylase inhibitors. ACS Med. Chem. Lett. 2014, 5, 628–633. [Google Scholar] [CrossRef] [PubMed]
  34. Hong, J.; Luesch, H. Largazole: From discovery to broad-spectrum therapy. Nat. Prod. Rep. 2012, 29, 449–456. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Marinedrugs 17 00333 g001 550
Figure 1. The representative natural histone deacetylases (HDAC) inhibitors and designed analogs of Largazole.
Figure 1. The representative natural histone deacetylases (HDAC) inhibitors and designed analogs of Largazole.
Marinedrugs 17 00333 g001
Marinedrugs 17 00333 sch001 550
Scheme 1. Synthesis of the analogs of Largazole.
Scheme 1. Synthesis of the analogs of Largazole.
Marinedrugs 17 00333 sch001
Marinedrugs 17 00333 g002 550
Figure 2. The concentration-response curves of the compounds in the enzymatic assays (HDAC 1, 2, 3, 8 and 6).
Figure 2. The concentration-response curves of the compounds in the enzymatic assays (HDAC 1, 2, 3, 8 and 6).
Marinedrugs 17 00333 g002
Marinedrugs 17 00333 g003 550
Figure 3. The concentration-response curves of Largazole and 16a in the cellular assays.
Figure 3. The concentration-response curves of Largazole and 16a in the cellular assays.
Marinedrugs 17 00333 g003
Table
Table 1. In vitro inhibition of human HDACs with Largazole and its analogs.
Table 1. In vitro inhibition of human HDACs with Largazole and its analogs.
CompoundIC50 ± SD (nM) aSelectivity (HDAC1/6)
HDAC1HDAC2HDAC3HDAC8HDAC6
Largazole228 ± 341520 ± 152002 ± 28120 ± 58>5000ND b
Largazole thiol2.0 ± 0.0 (1.2) c9.5 ± 0.2 (3.4) c14.4 ± 0.2 (3.5) c3.8 ± 0.2 (102) d121 ± 5.0 (49) c61 (40) c
16a385 ± 451817 ± 172303 ± 25255 ± 92>5000ND c
15a4.4 ± 0.221.0 ± 0.339 ± 28.5 ± 2.5300 ± 568
15b4.2 ± 0.316.2 ± 0.437.1 ± 0.717.6 ± 4.1338 ± 1780
SAHA19 ± 451 ± 649 ± 5328 ± 13811 ± 10.24
a Compounds were tested in 10-dose IC50 mode in duplicate with threefold serial dilution. b Not determined. c The data in the parentheses were those reported by Bradner and Williams in ref. [23]. d The data in the parentheses was reported by Leusch in ref. [34].
Table
Table 2. In vitro growth inhibition of several cells (IC50, µM) with Largazole and its analog 16a.
Table 2. In vitro growth inhibition of several cells (IC50, µM) with Largazole and its analog 16a.
CompoundIC50 a ± SD (µM)
A549HCT116MDA-MB-231SK-OV-3
Largazole0.46 ± 0.100.18 ± 0.01 (0.044) b1.37 ± 0.410.03 ± 0.01
16a0.52 ± 0.120.81 ± 0.133.85 ± 0.440.25 ± 0.13
a Compounds were tested in seven-dose IC50 mode in duplicate with four-fold serial dilution. b The data in the parentheses was reported by Leusch in ref. [9].

Share and Cite

MDPI and ACS Style

Zhang, B.; Shan, G.; Zheng, Y.; Yu, X.; Ruan, Z.-W.; Li, Y.; Lei, X. Synthesis and Preliminary Biological Evaluation of Two Fluoroolefin Analogs of Largazole Inspired by the Structural Similarity of the Side Chain Unit in Psammaplin A. Mar. Drugs 2019, 17, 333. https://doi.org/10.3390/md17060333

AMA Style

Zhang B, Shan G, Zheng Y, Yu X, Ruan Z-W, Li Y, Lei X. Synthesis and Preliminary Biological Evaluation of Two Fluoroolefin Analogs of Largazole Inspired by the Structural Similarity of the Side Chain Unit in Psammaplin A. Marine Drugs. 2019; 17(6):333. https://doi.org/10.3390/md17060333

Chicago/Turabian Style

Zhang, Bingbing, Guangsheng Shan, Yinying Zheng, Xiaolin Yu, Zhu-Wei Ruan, Yang Li, and Xinsheng Lei. 2019. "Synthesis and Preliminary Biological Evaluation of Two Fluoroolefin Analogs of Largazole Inspired by the Structural Similarity of the Side Chain Unit in Psammaplin A" Marine Drugs 17, no. 6: 333. https://doi.org/10.3390/md17060333

APA Style

Zhang, B., Shan, G., Zheng, Y., Yu, X., Ruan, Z. -W., Li, Y., & Lei, X. (2019). Synthesis and Preliminary Biological Evaluation of Two Fluoroolefin Analogs of Largazole Inspired by the Structural Similarity of the Side Chain Unit in Psammaplin A. Marine Drugs, 17(6), 333. https://doi.org/10.3390/md17060333

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop